Sandostatin LAR (octreotide acetate suspension for injection) demonstrated antitumor benefit in patients with metastatic neuroendocrine tumors (NETs) of the midgut, according to interim data presented at the 2009 Gastrointestinal Cancer Symposium of the American Society of Clinical Oncology.
After six months of treatment patients receiving Sandostatin LAR had a 66% reduction in risk of disease progression compared to patients taking placebo. This reduction is based on findings that Sandostatin LAR halted tumor growth in 69% of patients, compared with 39% of patients receiving placebo.
Patients who took Sandostatin LAR had no tumor progression for a median of 14.3 months, compared to six months for patients on placebo. This beneficial effect was seen in patients with either functioning (hormone secreting) or non functioning (non secreting) NETs.
“Sandostatin LAR has a proven track record of treating the severe diarrhea and flushing associated with neuroendocrine tumors and now this study demonstrates that Sandostatin LAR also helps control tumor growth in patients with metastatic neuroendocrine tumors of the midgut,” said PROMID Lead Investigator Professor Rudolf Arnold, Philipps University Marburg, Germany. “In addition, we saw the greatest benefit in those patients who were newly diagnosed and who had fewer liver metastases, underscoring the importance of early treatment.”
For more information click on the link below: